US 12,012,638 B2
Esophageal cancer detection kit or device, and detection method
Hiroko Sudo, Kamakura (JP); Hitoshi Nobumasa, Kamakura (JP); Satoko Kozono, Kamakura (JP); Satoshi Kondou, Kamakura (JP); Junpei Kawauchi, Kamakura (JP); Atsushi Ochiai, Kashiwa (JP); and Motohiro Kojima, Kashiwa (JP)
Assigned to TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Nov. 18, 2022, as Appl. No. 17/990,164.
Application 17/990,164 is a division of application No. 16/803,390, filed on Feb. 27, 2020, granted, now 11,542,558.
Application 16/803,390 is a division of application No. 15/317,857, granted, now 10,619,212, issued on Apr. 14, 2020, previously published as PCT/JP2015/067580, filed on Jun. 18, 2015.
Claims priority of application No. 2014-125036 (JP), filed on Jun. 18, 2014; and application No. 2015-070379 (JP), filed on Mar. 30, 2015.
Prior Publication US 2023/0118787 A1, Apr. 20, 2023
Int. Cl. C12Q 1/68 (2018.01); C12N 15/09 (2006.01); C12P 19/34 (2006.01); C12Q 1/6886 (2018.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [C12N 15/09 (2013.01); C12Q 1/68 (2013.01); G01N 33/53 (2013.01); G01N 33/574 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 6 Claims
 
1. A method for detecting esophageal cancer in a human subject, comprising:
measuring an expression level of hsa-miR-1233-5p in a blood, serum or plasma sample of the subject,
comparing the measured expression level of hsa-miR-1233-5p to a control expression level for a healthy subject;
detecting a decreased level of hsa-miR-1233-5p in the sample from the subject as compared to the control expression level;
wherein the decreased level of hsa-miR-1233-5p indicates that the subject has esophageal cancer; and
wherein the method further comprises treating the subject for the esophageal cancer or performing a diagnostic procedure on the subject with the esophageal cancer;
wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof; and
wherein the diagnostic procedure comprises esophagography, endoscopy, CT scan, MRI scan, endosonography, or ultrasonography.